Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9916977 | 0.73 | NPC1 (0.32) | SMN1; SMN2 | |
| SCHEMBL9916978 | 0.72 | PDK1 (0.31) | SMN1; SMN2 | |
| SCHEMBL9916030 | 0.71 | SMN1; SMN2 (0.38) | L3MBTL1CYP1A2CYP2C19GAAALDH1A1 | |
| SCHEMBL9916033 | 0.70 | RIPK1 (0.43) | L3MBTL1CYP1A2CYP2C19GAAALDH1A1 | |
| SCHEMBL9915939 | 0.69 | KMT2A (0.36) | L3MBTL1CYP1A2CYP2C19GAAALDH1A1 | |
| SCHEMBL9916047 | 0.68 | ALDH1A1 (0.37) | L3MBTL1CYP1A2CYP2C19GAAALDH1A1 | |
| SCHEMBL9915993 | 0.68 | ALDH1A1 (0.39) | L3MBTL1CYP1A2CYP2C19GAAALDH1A1 | |
| SCHEMBL9915938 | 0.67 | KMT2A (0.37) | L3MBTL1CYP1A2CYP2C19GAAALDH1A1 | |
| SCHEMBL9915996 | 0.62 | HSD11B1 (0.42) | L3MBTL1GAAALDH1A1MEN1KMT2A | |
| SCHEMBL9926307 | 0.61 | GRIN2D (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148954-A1 | N-ACYL-B-LACTAM DERIVATIVE, MACROMOLECULAR COMPOUND, AND PHOTORESIST COMPOSITION | KURARAY CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148954-A1 | N-ACYL-B-LACTAM DERIVATIVE, MACROMOLECULAR COMPOUND, AND PHOTORESIST COMPOSITION | COASY, ARCN1, CLTB | L3MBTL1 2296/4885CYP1A2 1235/4885CYP2C19 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.